ScandiDos AB
The answer first
Does ScandiDos beat the market?
No, ScandiDos has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 18% of Nordic stocks
- Quality22
- Value74
- Trend4
No. 134 of 195 in healthcare
Max for seven days
Follow ScandiDos with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about ScandiDos
Your first answer is free, no account needed.
Do you own ScandiDos, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with ScandiDos and a few more. Free, no card.
Super Stock+45.9%In short
- ScandiDos has fallen 60.2% over the past year, including dividends.
- Overall, ScandiDos ranks better than 18% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 82.6%. The price is 97.0% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 18% of Nordic stocks.
No. 134 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 166 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.05
- Asset turnoverSales divided by everything the company owns0.69
- Return on equityProfit divided by equity−17.4%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 17 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity0.5
- P/SPrice divided by sales0.5
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 183 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−52.0%
- 6 months−59.2%
- 9 months−57.9%
- 12 months−60.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own ScandiDos
One fund we follow owns ScandiDos. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About ScandiDos
ScandiDos AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 25 employees.
ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and advanced software solutions in the United States, Europe, Asia, and internationally. The company offers Delta4 products comprising Delta4 Phantom+ and Delta4Phantom+MR; Delta4 HexaMotion; and Delta4Insight, Delta4DVH Anatomy, Delta4 Machine QA, and Delta4 Statistics Module for the quality assurance in advanced radiation therapy techniques, including VMAT, RapidArc, IMRT, and tomotherapy. It also provides installation services, service agreements, and additional services. It sells its products through sales offices and distributors.


See the full analysis of ScandiDos.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card